pharmaphorum

FEBRUARY 18, 2021

Mutations may alter neutralisation by affecting spike function rather than antigen response and its also unclear from this study how the T-cell response is affected. The body’s immune response to the coronavirus is not limited to antibodies with CD8+ T-cells also playing roll combating infections.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

pharmaphorum

FEBRUARY 9, 2022

However, the industry is constantly looking to discover the next frontier in treatment development and technology to provide more effective, safer treatments to patients. One area that is gathering increasing levels of interest is the development of cancer vaccines. A broad front. Prior success.

Vaccination 128

Vaccination Vaccine Clinical Trials Clinical Trials 128

pharmaphorum

NOVEMBER 30, 2020

“NAbs are antibodies that are part of the humoral response of the adaptive immune system,” explains Rich Horgan, founder and president of Cure Rare Disease (CRD), a nonprofit biotech developing CRISPR therapeutics for Duchenne muscular dystrophy (DMD).

Gene Therapy 104

Gene Therapy Gene Antibody Clinical Trials 104

pharmaphorum

AUGUST 23, 2021

The COVID-19 pandemic accelerated the development of mRNA-based vaccines, and its influence has now extended to DNA-based shots as well, with Zydus Cadila’s ZyCoV-D getting emergency use authorisation in India. The company also says that it can update the vaccine very easily to deal with mutations in the virus.

DNA 98

DNA Vaccination Vaccine Genetic Engineering 98

pharmaphorum

FEBRUARY 14, 2022

Like Shingrix, CRV-101 is a subunit vaccine based on the glycoprotein E (gE) antigen of the herpes zoster virus, delivered alongside an adjuvant to boost the immune response. The biotech has been looking for a development partner for the shot as a chickenpox vaccine.

Vaccination 52

Vaccination Vaccine Immune Response Trials 52

pharmaphorum

DECEMBER 21, 2020

The agreement sees San Diego-based Janux in line for around $500 million in milestones apiece for two T-cell engager therapies – which bind to a tumour cell and recruit a patient’s T cells to eradicate tumour cells – that will be developed using Janux’ TRACTr platform.

Immune Response 52

Immune Response Sales Antibody Pharma Companies 52

pharmaphorum

APRIL 26, 2022

Compared to a ‘critical organ’ that had been largely ignored, companies working to develop microbiome-based therapies believe there is untapped potential in the area. Ben Hargreaves speaks to companies that are developing therapies not just in gastrointestinal conditions but also in broader areas, such an immuno-oncology.

Containment 108

Containment Development Production Immune Response 108

The Pharma Data

DECEMBER 11, 2020

Thermo Fisher joined forces with the University of Oxford to harness its academic research capabilities in quantifying IgG antibodies and understanding each patient’s immune response to SARS-CoV-2. 200 carrier pods acquired for increased demand of Covid-19 vaccine refrigerated storage.

Antibody 52

Antibody Vaccination Vaccine Containment 52

pharmaphorum

JANUARY 7, 2021

The California-based company has signed a non-exclusive license with Pfizer to supply its 89Zr CD8 Immuno-PET agent, which can be used to image CD8 T cells in cancer patients. Equally important to the company is the safety data gathered as the technology is used as the pharma companies use it to guide development of cancer immunotherapies.

Doctors 52

Doctors Doctor Immune Response Pharma Companies 52

Drug Discovery World

MAY 6, 2024

In this article, DDW’s Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. The oldest, still active pharmaceutical company worldwide, Merck, started life in 1668 in Darmstadt, Germany. The CDD will sponsor and manage KWF-supported trials.

Drugs 59

Drugs Life Science Gene Editing Gene 59

The Pharma Data

NOVEMBER 27, 2020

Vaccine development to cure coronavirus is at an all-time high after Pfizer and BioNTech announced they had success with a possible vaccine candidate. UK firm develops solution for identifying whether patients are actually infectious from a virus or not. Read on to for the full insight.

Vaccination 52

Vaccination Vaccine Immune Response Marketing 52

Delveinsight

AUGUST 4, 2021

Age is one of the major contributors to the development of certain Neurological Disorders such as Parkinson’s disease and Alzheimer’s. Similarly, genetics, immune response, and environmental factors also influence the occurrence of Neurological Conditions. are involved in developing therapies for Acute Ischemic Stroke (AIS).

Marketing 98

Marketing Genetics Development Clinical Development 98

XTalks

AUGUST 17, 2020

Immunotherapy continues to be a burgeoning field, with immune-based therapies being among the leading treatments being developed in oncology and autoimmunity. Treatment vaccines : these boost the immune system responses to target cells. Immune system modulators (i.e. Nature by Design.

Protein 98

Protein Engineer Immune Response In-Vivo 98

XTalks

SEPTEMBER 5, 2023

Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

AUGUST 13, 2020

In 2018 the research firm Reputation Institute ranked Pfizer’s reputation at rock bottom on a list of 22 pharma companies – and none of them ranked highly against other sectors! There are many other mega pharmaceutical companies in the kill-COVID game: Johnson & Johnson, Sanofi, AstraZeneca, GSK and Roche included.

Branding 90

Branding Vaccination Vaccine Filler 90

pharmaphorum

SEPTEMBER 20, 2022

Vaccines have transitioned from being a largely unloved area of the industry, with multiple big pharma companies divesting their vaccine divisions , to the biggest revenue drivers seen in recent years. This all comes down to the impact of the pandemic.

Vaccination 94

Vaccination Vaccine Immune Response Antibody 94

XTalks

AUGUST 18, 2021

While infectious disease experts and drug companies have rightfully spent the last 18 months developing therapeutics and vaccines targeting SARS-CoV-2 and COVID-19, another global threat to public health — antimicrobial resistance (AMR) — has, and will continue to, persist until similar direct action is taken.

Development 105

Development Bacteria Drugs Vaccination 105

World of DTC Marketing

SEPTEMBER 28, 2020

A single dose of Johnson & Johnson’s J&J experimental COVID-19 vaccine produced a strong immune response against the novel coronavirus in an early-to-mid stage clinical trial, according to interim published results. J&J received more than $1 billion from the U.S.

Vaccination 163

Vaccination Vaccine Clinical Trials Clinical Trials 163